Efficacy and safety of pyrotinib combined with albumin‐bound paclitaxel as first‐line treatment for HER2‐positive metastatic breast cancer in patients previously treated with adjuvant and/or neoadjuvant trastuzumab therapy: The stage 1 results of a single‐arm, phase 2 prospective clinical trial
Clinical and Translational Medicine · 2024
DOI: 10.1002/ctm2.1687 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Clinical and Translational Medicine, 2024. Verfasst von Xiaochu Man und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Scie…. Hauptthemen laut MEDLINE: Breast Neoplasms, Trastuzumab, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jiangsu Hengrui Medicine Co, Ltd, Chinese Society of Clinical Oncology-Heng Rui Cancer Research Fund, Shandong Provincial Natural Science Foundation Cancer Prevention Joint Fund.
Abstract (Originalsprache)
Objective
It has been observed that the prognosis of patients with HER2‐positive metastatic breast cancer has improved significantly with HER2‐targeted agents. However, there is still a lack of evidence regarding first‐line anti‐HER2 treatment options for patients who have received adjuvant and/or neoadjuvant trastuzumab for HER2‐positive metastatic breast cancer. Besides, there are no reliable markers that can predict the efficacy of anti‐HER2 treatment in these patients.
Methods
Patients who have received adjuvant and/or neoadjuvant trastuzumab for HER2‐positive metastatic breast cancer were enrolled. Pyrotinib plus albumin‐bound paclitaxel were used as first‐line treatment. The primary endpoint was the objective response rate (ORR). The safety profile was also assessed. In order to explore predictive biomarkers using Olink technology, blood samples were collected dynamically.
Results
From December 2019 to August 2023, the first stage of the study involved 27 eligible patients. It has not yet reached the median PFS despite the median follow‐up being 17.8 months. Efficacy evaluation showed that the ORR was 92.6%, and the DCR was 100%. Adverse events of grade 3 or higher included diarrhoea (29.6%), leukopenia (11.1%), neutropenia (25.9%), oral mucositis (3.7%), and hand‐foot syndrome (3.7%). Toll‐like receptor 3 (TLR3) and Proto‐oncogene tyrosine‐protein kinase receptor (RET) were proteins with significant relevance to PFS in these patients.
Conclusions
This study demonstrates that pyrotinib plus albumin‐bound paclitaxel as a first‐line treatment regimen shows good efficacy and manageable safety for patients who have received adjuvant and/or neoadjuvant trastuzumab for HER2‐positive metastatic breast cancer. Besides, a significant association was identified between the expression levels of TLR3 and RET and the PFS in patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
- Department of Breast Surgery, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
- Department of Surgery, The 960th Hospital of the PLA Joint Logistics Support Force, Jinan, China.
- Department of Medical Oncology, Qingdao Municipal Hospital (Group), Jinan, China.
- Department of Surgery, Liaocheng Tumor Hospital, Liaocheng, China.
ORCID-Profile: Linlin Wang, Huihui Li
Förderung
- Jiangsu Hengrui Medicine Co, Ltd
- Chinese Society of Clinical Oncology-Heng Rui Cancer Research Fund
- Shandong Provincial Natural Science Foundation Cancer Prevention Joint Fund
- Shanghai Cancer Prevention and Cancer Cancer Development Foundation
Zitieren
APA
Man, X., Huang, J., Sun, S., Zhou, D., Zhang, B., Fang, S., Zheng, F., Li, C., Wang, X., Huang, W., Wang, L., He, Q., Fu, H., Zhang, Y., Liu, C., Dong, L., Zhao, X., Xu, L., Sun, X., …, & Li, H. (2024). Efficacy and safety of pyrotinib combined with albumin‐bound paclitaxel as first‐line treatment for HER2‐positive metastatic breast cancer in patients previously treated with adjuvant and/or neoadjuvant trastuzumab therapy: The stage 1 results of a single‐arm, phase 2 prospective clinical trial. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.1687
Vancouver
Man X, Huang J, Sun S, Zhou D, Zhang B, Fang S, et al. Efficacy and safety of pyrotinib combined with albumin‐bound paclitaxel as first‐line treatment for HER2‐positive metastatic breast cancer in patients previously treated with adjuvant and/or neoadjuvant trastuzumab therapy: The stage 1 results of a single‐arm, phase 2 prospective clinical trial. Clinical and Translational Medicine. 2024. doi:10.1002/ctm2.1687
BibTeX
@article{Man2024,
author = {Man, Xiaochu and Huang, Jie and Sun, Shujuan and Zhou, Dongdong and Zhang, Baoxuan and Fang, Shu and Zheng, Fangchao and Li, Chao and Wang, Xinzhao and Huang, Wei and Wang, Linlin and He, Qingqing and Fu, Hui and Zhang, Yan and Liu, Changrui and Dong, Lin and Zhao, Xianguang and Xu, Liang and Sun, Xiao and Fan, Bingjie and Song, Lihua and Zhou, Zhengbo and Yu, Jinming and Li, Huihui},
title = {Efficacy and safety of pyrotinib combined with albumin‐bound paclitaxel as first‐line treatment for HER2‐positive metastatic breast cancer in patients previously treated with adjuvant and/or neoadjuvant trastuzumab therapy: The stage 1 results of a single‐arm, phase 2 prospective clinical trial},
journal = {Clinical and Translational Medicine},
year = {2024},
doi = {10.1002/ctm2.1687}
}
EUVIMED